NCT05679349 · Ronald Myers
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
What this study is about
This clinical trial tests how well providing education improves screening for lung cancer in patients with a history of smoking. Screenings may help doctors find lung cancer sooner when it may be easier to treat. Education and counseling may be an effective method to help providers and patients learn about lung cancer screening.
View original scientific description
This clinical trial tests how well providing education improves screening for lung cancer in patients with a history of smoking. Screenings may help doctors find lung cancer sooner when it may be easier to treat. Education and counseling may be an effective method to help providers and patients learn about lung cancer screening. Providing education and decision counseling to providers and patients may increase lung cancer screening.
Interventions
OTHER
Survey Administration
Complete survey
OTHER
Educational Activity
Undergo online shared decision making training and distance learning
OTHER
Survey Administration
Complete survey
OTHER
Electronic Health Record Review
Undergo electronic health record review
OTHER
Educational Activity
Undergo online shared decision making training and distance learning
OTHER
Counseling
Undergo shared decision making counseling
OTHER
Survey Administration
Complete survey
OTHER
Electronic Health Record Review
Undergo electronic health record review
Primary outcome measures
Completion of initial lung cancer screening (LCS)
Time frame: Within 4 months of randomization
LCS will be assessed through an endpoint electronic medical records (EMR) search, supplemented with a question on the participant endpoint survey to capture any LCS performed outside the health system and/or not captured in the EMR.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- PRACTICE LEVEL:
- Primary care practice (family medicine, geriatrics, internal medicine) in one of the 4 participating health systems
- Practice using the main electronic medical record (EMR) of each system, in order to run appropriate patient recruitment reports
- Practice with at least 50% of practice providers (physicians and advanced care providers) consenting to participate
- PATIENT LEVEL:
- Have an office or telemedicine established patient visit scheduled with a primary care provider in one of the participating practices within next 14 to 25 days
- 50 to 77 years of age
- Have at least a 20-pack-year smoking history (based on self-report at baseline eligibility assessment)
- Currently smoke or have quit smoking within the past 15 years (based on self-report at baseline eligibility assessment)
- Able to communicate in English or Spanish (determined at baseline eligibility assessment)
Exclusion criteria
- PATIENT OUTREACH:
- Any lung computed tomography (CT) or low-dose computed tomography (LDCT) scan in the past 11 months, current procedural terminology (CPT) Codes are as follows
- G0297 - LDCT screening
- 71250 - CT w/o contrast
- 71260 - CT w/ contrast
- 71270 - CT with and w/o contrast
- 71275 - CT angiography chest
- 78815 - Positron emission tomography computed tomography (PET CT) skull base to mid-thigh
- 78816 - PET CT whole body
- Prior history of lung cancer (The patient's problem list includes a problem with an international classification of diseases (ICD10) code of "Z85.118" or one beginning with "C34.", or by self-report at baseline eligibility assessment)
- Recent hospitalization (Admission date within the last 60 days listed in electronic health record (EHR), or by self-report at baseline eligibility assessment)
- Dementia (diagnosis codes F03.90 or F03.91) in EHR
Where
- Philadelphia, Pennsylvania
Collaborators
National Cancer Institute (NCI)
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced May 29, 2026 · Source of record for eligibility and locations